TrialThe British journal of dermatology2020

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

A B Kimball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.